NT5E is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for fallopian tube carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and fallopian tube carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for fallopian tube undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and fallopian tube undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for malignant ovarian mixed epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and malignant ovarian mixed epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for malignant ovarian neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and malignant ovarian neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for malignant peritoneal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and malignant peritoneal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for ovarian carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and ovarian carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for ovarian undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and ovarian undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for primary peritoneal carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and primary peritoneal carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for primary peritoneal endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for primary peritoneal serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NT5E is an inclusion criterion in 1 clinical trial for primary peritoneal undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NT5E status and primary peritoneal undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].